Jakavi offers new treatment option in myelofibrosis

Jakavi (ruxolitinib) is a selective inhibitor of JAK 1 and 2 for use in disease-related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia.

The starting dose of Jakavi is dependent on baseline platelet count
The starting dose of Jakavi is dependent on baseline platelet count

PHARMACOLOGY

Ruxolitinib inhibits the Janus-associated kinases (JAK) 1 and 2, which mediate the signalling of molecules involved in haematopoiesis and immune function.1 In myelofibrosis, there is typically a dysfunction of the JAK pathway.

CLINICAL STUDIES

Ruxolitinib displayed efficacy in two double-blind studies in patients with intermediate-2 or high-risk myelofibrosis. The first (COMFORT-I) compared ruxolitinib with placebo and the second (COMFORT-II) used best available therapy (BAT) as the comparator treatment.2,3

Reduced spleen volume

In COMFORT-I (n=309), 41.9% of ruxolitinib patients achieved a ≥35% reduction in spleen volume at 24 weeks compared with 0.7% of placebo patients (p<0.001). This reduction was maintained for 48 weeks or more in 67% of those who responded. Ruxolitinib was also associated with a significant survival advantage compared with placebo (13 versus 24 deaths, hazard ratio 0.5; p=0.05).2

In COMFORT-II (n=219), 28% of patients who received ruxolitinib had a ≥35% reduction in spleen volume at 48 weeks compared with 0% of patients who received BAT (p<0.001).3 In addition, there was a 56% reduction in mean palpable spleen length at 48 weeks in the ruxolitinib group compared with a 4% increase in the BAT group. The most common therapies in the BAT group were hydroxycarbamide and glucocorticoids.3

Well tolerated

Ruxolitinib was associated with symptom improvement and was generally well tolerated, with anaemia and thrombocytopenia the most commonly reported adverse effects.2,3

References:

1.    Jakavi Summary of Product Characteristics, August 2012
2.    Verstovsek S et al. N Engl J Med 2012; 366: 799-807.
3.    Harrison C et al. N Engl J Med 2012; 366: 787-98.

View Jakavi drug record

Further information: Novartis

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.